2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Apolipoprotein
  5. apoB Isoform

apoB

Apolipoprotein B (apoB) is the principal structural apolipoprotein of atherogenic lipoproteins, including chylomicrons, very-low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), low-density lipoproteins (LDL), and lipoprotein(a), and is essential for lipoprotein assembly and lipid transport throughout the circulation[1][2]. ApoB-containing lipoproteins drive lipid trafficking through pathways that coordinate intestinal dietary fat absorption and hepatic lipoprotein secretion, thereby linking systemic lipid metabolism with cholesterol delivery and clearance mechanisms[1][3]. Mechanistically, apoB100 functions as the primary ligand for LDL receptor-mediated uptake of LDL particles, enabling receptor-dependent lipoprotein catabolism and regulating the persistence of circulating atherogenic particles[1][4]. In cardiovascular disease, retention and accumulation of apoB-containing lipoproteins within the arterial wall represent key initiating events in atherosclerotic plaque formation, and elevated apoB particle burden is strongly associated with atherosclerotic cardiovascular risk[1][2][5]. Compared with related isoforms, apoB100 is synthesized in the liver and is present in VLDL, IDL, LDL, and lipoprotein(a), whereas apoB48 is generated in the intestine through APOB mRNA editing and functions primarily in chylomicron formation and dietary lipid transport[1][4][6]. Importantly, apoB48 lacks the LDL receptor-binding domain present in apoB100, resulting in distinct roles in lipoprotein metabolism despite their common genetic origin[3][4]. For experimental applications, apoB and its isoforms are widely used to investigate lipoprotein assembly, remnant metabolism, atherosclerosis mechanisms, and cardiovascular risk assessment in both clinical and preclinical models[1][2][5].

apoB Related Products (4):

Cat. No. Product Name Effect Purity
  • HY-108764
    Mipomersen sodium
    		Inhibitor
    Mipomersen sodium (ISIS 301012) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen sodium can be used for the research of homozygous familial hypercholesterolemia (HoFH).
  • HY-18778
    Obicetrapib
    		Inhibitor 99.93%
    Obicetrapib (TA-8995; DEZ-001) is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD).
  • HY-148647
    Mipomersen
    		Inhibitor
    Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen can be used for the research of homozygous familial hypercholesterolemia (HoFH).
  • HY-179364
    PLTP-IN-1
    PLTP-IN-1 (cpd B) is a selective phospholipid transfer protein (PLTP) inhibitor with an IC50 of 1.6 μM. PLTP-IN-1 can block the phospholipid transfer mediated by PLTP and reduce the secretion of apolipoprotein B. PLTP-IN-1 has no effect on the level of triglycerides. PLTP-IN-1 can be used for the research of metabolic disease, such as hyperlipidemia.